Jane Street Group LLC Buys New Shares in Inhibrx, Inc. (NASDAQ:INBX)

Jane Street Group LLC purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 88,419 shares of the company's stock, valued at approximately $1,362,000. Jane Street Group LLC owned approximately 0.61% of Inhibrx at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. HighTower Advisors LLC bought a new position in Inhibrx during the fourth quarter worth about $12,039,000. Walleye Capital LLC bought a new position in shares of Inhibrx during the 4th quarter worth approximately $8,932,000. Slotnik Capital LLC bought a new position in shares of Inhibrx during the 4th quarter worth approximately $5,975,000. Geode Capital Management LLC acquired a new position in shares of Inhibrx during the 4th quarter worth approximately $3,930,000. Finally, Castalian Partners LLC bought a new stake in Inhibrx in the 4th quarter valued at $2,950,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Inhibrx Stock Performance

Shares of INBX stock opened at $12.47 on Tuesday. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $34.71. The company has a market capitalization of $180.52 million and a price-to-earnings ratio of 0.11. The company has a 50-day simple moving average of $12.59 and a 200 day simple moving average of $13.61.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($2.55) by ($0.25). Sell-side analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a "market perform" rating on shares of Inhibrx in a research report on Thursday, May 15th.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.